Author of

• 36050

  +

  P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics (ID 227)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36066

    +

    P01.14 - Safety and Feasibility of Standard Dosing Carboplatin AUC 5 Every 3rd Weeks With Daily Navelbine® 20/30mg During 4 Cycles, Treating Advanced NSCLC (ID 726)

    00:00 - 00:00  |  Presenting Author(s): Maria Kandi
    • Abstract
    • Slides

    Introduction
    

    Non-small cell lung cancer (NSCLC) is the second most common cancer in the world. The goal for treatment of patients with metastatic NSCLC is to relieve symptoms, prolong survival and improve quality of life. Palliation needs to be balanced against survival and toxicity. Metronomic regimens, small frequent doses of chemotherapy, have been proposed to achieve lower treatment-related toxicity while maintaining or even improving efficacy. The hypothesis is that the frequent administration aims to expose tumor cells continuously to the drug and prevent their ability to regenerate between the chemotherapy series resulting in even better tumor control. This study assesses the tolerability of carboplatin in combination with metronomic vinorelbine during 12 weeks of treatment.

    Methods
    

    From May 2018 to February 2019 patients with incurable NSCLC, candidates for 1^st-line chemotherapy (PD-L1<50%), were included. This study was investigator initiated and designed as a prospective non-randomized, open-label, single-arm, safety and feasibility study. Patients received standard chemotherapy, carboplatin AUC-5 every 3^rd week and metronomic oral Navelbine^® (20/30 mg) daily for 12 weeks, followed by CT scans for evaluation. Maximum of 4 cycles were delivered. Treatment toxicity was registered online, as patient-reported outcome, every 3^rd week during treatment.

    Results
    

    Twenty patients were included. Median age was 70.5 years (range 49-83); 19 (95%) had adenocarcinoma. Fourteen (70%) received all four cycles. Two withdrew their consent. Two had decline in performance-status and two had disease progression and received only 1-2 cycles of treatment. Majority had CTCAE grade-1 toxicity such as fatigue, constipation and diarrheas. Two had febrile neutropenia and recovered. None had CTCAE grade-5 toxicity.

    Conclusion
    

    This is, to our knowledge, the first and only study evaluating a combination regimen with standard carboplatin given together with metronomic daily oral Navelbine for advanced NSCLC. Doublet chemotherapy with oral Navelbine daily is a safe option, although there is a call for randomized phase II/III trial with carboplatin-based doublet regimen in metronomic strategy, where one arm including maintenance oral Navelbine in advanced NSCLC.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.